T3 Companies’s Esperion Therapeutics ESPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-82,500
Closed -$261K – 221
2026
Q2
$261K Buy
+82,500
New +$231K 0.28% 71

Other funds holding ESPR

T3 Companies's ESPR Position: Q3 2026 in Review

T3 Companies sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 82,500 shares — an estimated $261K sold.

T3 Companies first reported a position in ESPR in Q2 2026 and held it in 1 quarter. The position peaked at $261K in Q2 2026. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

  • T3 Companies reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
  • T3 Companies sold 82,500 Esperion Therapeutics shares in Q3 2026, an estimated $261K.
  • T3 Companies first reported a position in Esperion Therapeutics in Q2 2026 and held it in 1 quarter.
  • T3 Companies's Esperion Therapeutics position peaked at $261K in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on T3 Companies's 13F filing for Q3 2026, filed 22 Oct 2026.